Table 1.
Sample number | Profiled on SNP arrays? | Tissue | Tissue diagnosis | Tumor content (%) | Patient diagnosis | Stage | Age (years) | Sex |
---|---|---|---|---|---|---|---|---|
HF-18411 | Yes | Pancreas | Adenocarcinoma | 20 | Pancreatic cancer | T4N1M0 (IVA) | 48 | Female |
HF-18996 | Yes | Pancreas | Adenocarcinoma | 30 | Pancreatic cancer | T2N0M0 | 49 | Female |
HF-18998 | Yes | Pancreas | Adenocarcinoma | 30 | Pancreatic cancer | T2N0M0 | 50 | Male |
HF-19000 | Yes | Pancreas | Adenocarcinoma | 10 | Pancreatic cancer | T2N0M0 | 59 | Female |
HF-16979 | No | Pancreas | Adenocarcinoma ductal | 20 | Pancreatic cancer | pT3pN1pMX (IIB) | 60 | Female |
HF-18764 | No | Pancreas | Adenocarcinoma | 30 | Pancreatic cancer | T3N0M0 (II) | ||
HF-16976 | No | Pancreas | Adenocarcinoma ductal | 20 | Pancreatic cancer | pT3pN1bpMX (III) | 64 | Male |
HF-2035 | No | Pancreas | Adenocarcinoma | 75 | Adenocarcinoma | 72 | Female | |
HF-18409 | No | Pancreas | Adenocarcinoma | 30 | Pancreatic cancer | T3N0M0 (II) | 63 | Female |
HF-16359 | No | Pancreas | Adenocarcinoma ductal | 10 | Pancreatic cancer | T 3N0M0R1 (II) | 66 | Female |
HF-16349 | No | Pancreas | Adenocarcinoma ductal | 10 | Pancreatic cancer | T3N1M0R 0 (III) | 50 | Male |
HF-16345 | Yes | Pancreas | Adenocarcinoma ductal | 20 | Pancreatic cancer | T4N 1bM0R0 (IVA) | 75 | Female |
HF-16975 | No | Pancreas | Adenocarcinoma ductal | 10 | Pancreatic cancer | pT3pN1pMX (IIB) | 69 | Female |
HF-16980 | Yes | Pancreas | Adenocarcinoma ductal | 10 | Pancreatic cancer | pT3pN1pMX (IIB) | 68 | Female |
HF-17928 | No | Pancreas | Carcinoma, neuroendocrine | 90 | Pancreatic cancer | T3N0M0 (II) | 79 | Male |
HF-17700 | No | Pancreas | Inflammation and fibrosis | <5% | Pancreatic cancer | T4N0M0 (IVa) | Male |